Comparative Benchmarking
In the context of the broader market, RADX competes directly with industry leaders such as DCGO and XGN. With a market capitalization of $54.23M, it holds a significant position in the sector. When comparing efficiency, RADX's gross margin of N/A stands against DCGO's 27.25% and XGN's 55.35%. Such benchmarking helps identify whether Radiopharm Theranostics Ltd is trading at a premium or discount relative to its financial performance.
